FiercePharma is a news organisation based in Newton, Massachusetts, that analyses and reports on a variety of news from the pharmaceutical industry, including tracking of regulatory approvals, payer negotiations, manufacturing, marketing, patent fights, government investigations and regulation and M&A deals.

Feds join lawsuits claiming Insys used strip club visits, super-doses and more to boost Subsys sales

Prosecutors have already charged Insys founder John Kapoor and won guilty pleas from two characters in an ongoing kickbacks probe. Now, the Justice Department has escalated the case by joining in with whistleblowers who’ve detailed a stunning range of techniques the company allegedly used to push its powerful opioid painkiller. The […]

Skepticism on the wane? Reputation study says U.S. patient groups give props to pharma

Could U.S. patient groups be warming up to pharma? Skepticism seems to be on the wane—at least by some measures, according to PatientView’s annual corporate reputation study. Patient groups in the U.S. rated pharma companies’ patient-centricity, integrity and patient group partnerships much higher in this year’s study, which compared 2017 to 2016. Ratings […]

Fosun joins Aurobindo, PE firms in final bids for Novartis’ $2B U.S. generics assets: report

It turns out India’s Aurobindo is not the only one hot to buy a portfolio of Novartis’ U.S. generic assets, including its dermatology business.  China’s Fosun Pharma and private equity firms Apollo Global Management and CVC Capital Partners have also been shortlisted to make final offers, Bloomberg reported, citing people with knowledge […]

AstraZeneca's respiratory rivalry with GlaxoSmithKline takes a hit with Fasenra's phase 3 fail

AstraZeneca’s ambitions for keeping pace with GlaxoSmithKline in the severe COPD market just took a big hit. In a late-stage COPD trial released Friday, the British drugmaker’s blockbuster hopeful Fasenra didn’t beat placebo at holding off episodes when symptoms suddenly worsen. The study, dubbed Galathea, examined the drug as an add-on to dual- or […]

Ironwood and Allergan revamp IBS site with symptom-forward vibe and patient art

Allergan and Ironwood want to help people talk about their guts with their doctors—specifically, their possible IBS symptoms. The two pharma partners recently relaunched with a symptom-focused mission aimed at empowering patients. The two companies comarket Linzess, which is approved to treat irritable bowel syndrome with constipation (IBS-C) and chronic […]